Optimal use of bendamustine in chronic lymphocytic leukemia, non-hodgkin lymphomas, and multiple myeloma: Treatment recommendations from an international consensus panel

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 1, 2010, Pages 21-27

  Cheson, Bruce D ^a   Wendtner, Clemens Martin ^b   Pieper, Angelika ^c   Dreyling, Martin ^d   Friedberg, Jonathan ^e   Hoelzer, Dieter ^f   Moreau, Philippe ^g   Gribben, John ^h   Knop, Stefan ⁱ   Montillo, Marco ^j   Rummel, Mathias ^k  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MundiPharma International   (United Kingdom)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^f Onkologikum Frankfurt   (Germany)

^g NANTES UNIVERSITY HOSPITAL   (France)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY OF WÜRZBURG   (Germany)

^j OSPEDALE NIGUARDA CA GRANDA   (Italy)

^k JUSTUS LIEBIG UNIVERSITY   (Germany)

more..

Author keywords

Alkylating agent; Non Hodgkin's lymphoma; Phase I trial; Refractory; Relapsed; Rituximab

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; FLUDARABINE; MITOXANTRONE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONSENSUS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; INFECTION; INTERNATIONAL COOPERATION; LEUKOPENIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; STANDARDIZATION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; XEROSTOMIA; DRUG ADMINISTRATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS;

EID: 77953670179     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.002     Document Type: Review

References (35)

1. Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009; 27:4378-84.
2. Friedberg JW, Cohen P, Chen L, et al. Bendamustine in patients with rituximab refractory and alkylator-refractory, indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter single-agent study. J Clin Oncol 2008; 28:204-10.
3. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer 2009; 116:106-14.
4. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27:1492-1501.
5. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14:309-17. (Pubitemid 351378007)
6. Hoffken K, Merkle K, Schonfelder M, et al. Bendamustine as salvage treatment in patients with advanced progressive breast cancer: a phase II study. Cancer Res Clin Oncol. 1998; 124:627-32. (Pubitemid 28552999)
7. Schoffski P, Hagedorn T, Grunwald V, et al. Repeated administration of short infusions of bendamustine: a phase I study in patients with advanced progressive solid tumors. J Cancer Res Clin Oncol 2000; 126:41-7. (Pubitemid 30006350)
8. Schoffski P, Seeland G, Engel H, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progresive solid tumors. Ann Oncol 2000; 11:729-34.
9. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered day 1 + 2 every 3 weeks in patients with solid tumors. Br J Cancer 2007; 96:1692-8. (Pubitemid 46847200)
10. Rasschaert M, Schrijvers D, Van den Brande J, et al. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 2007; 18:587-95. (Pubitemid 46597413)
11. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's lymphomas. J Cancer Res Clin Oncol 2002; 128:603-9. (Pubitemid 35435557)
12. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 2005; 90:1357-64. (Pubitemid 41503651)
13. Heider A, Niederle N. Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin's lymphomas. Anticancer Drugs 2001; 12:725-9. (Pubitemid 33001185)
14. Niederle N, Balleisen L, Heit W, et al, et al. Bendamustine vs. fludarabine as second-line treatment for patients with chronic lymphocytic leukemia - first interim results of a randomized study. Ann Oncol 2008; 19(suppl 4): (abstract 379).
15. Kath R, Blumenstengel K, Fricke HJ, et al. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 2001; 127:48-54.
16. Lissitchkov T, Arnaudov G, Peytchev D, et al. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 2006; 132:99-104. (Pubitemid 41752051)
17. Ponisch W, Mitrou PS, Merkle K, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006; 132:205-12. (Pubitemid 43144255)
18. Knop S, Straka C, Haen M, et al. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005; 90:1287-8. (Pubitemid 41375295)
19. Owen JS, Melhem M, D'Andrea D, et al. Population pharmacokinetics of bendamustine and metabolites in patients with indolent non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Pharm Ther 2008; 83(suppl 1):S54-5.
20. Fischer K, Stilgenbauer S, Schweighofer CD, et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocyic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG). Blood 2008; 112:128 (abstract 330).
21. Byrd JC, Peterson B, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6-14. (Pubitemid 36025880)
22. Cheson BD, Friedberg J, Kahl BS, et al. Bendamustine produces durable responses with an acceptable long-term safety profile in patients with rituximabrefractory non-Hodgkin's lymphoma. A pooled analysis. Blood 2009; 114:1049 (abstract 268).
23. Rummel MJ, Al-Batran S, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23:3383-9.
24. Robinson KS, Williams ME, van der Jagt RH, et al. Bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma: a phase II multicenter study. J Clin Oncol 2008; 26:4473-9.
25. Rummel MJ, Niederle N, Maschmeye G, et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:168-9 (abstract 405).
26. Weidmann E, Kim SZ, Rost A, et al. Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2002; 13:1285-9. (Pubitemid 34960138)
27. Weide R, Hess G, Koppler H, et al. High anti-lymphoma activity of bendamustine/ mitoxantrone/rituximab in reituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007; 48:1299-306. (Pubitemid 47082223)
28. Matous J, Letzer J, Rosen P, et al. Bortezomib (V), bendamustine (B), and rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): dose finding results of the VERTICAL study. J Clin Oncol 2009; 27(suppl):442s (abstract 8535).
29. Ponisch W, Rozanski M, Goldschmidt H, et al. Combined bendamustine, prednisolone and thalidomide for refractory or relapsede multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a phase I clinical trial. Br J Haematol 2008; 143:191-200.
30. Fenk R, Michael M, Zohren F, et al. Escalation therapy with bortezomib, dexamethasone and bendamustine for patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2007; 48:2345-51. (Pubitemid 350253466)
31. Cheson BD, Frame J, Vena D, et al. Tumor lysis syndrome as a rare complication of fludarabine therapy in chronic lymphocytic leukemia. J Clin Oncol 1998; 16:2305-12.
32. Hummel M, Buchheidt D, Reiter S, et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur J Haematol 2005; 75:518-21. (Pubitemid 41687787)
33. Preiss R, Teichert J, Poenisch W, et al. Bendamustine pharmacokinetics and safety are not afflicted by impaired renal function in patients with multiple myeloma. Blood 2003; 102:381-2b (abstract 5254).
34. Treanda (bendamustine hydrochloride) [prescribing information]: Frazer, PA: Cephalon; 2008.
35. Burchardt CA, Brugger W, Maschmeyer G, et al. Peripheral blood stem cell mobilization after bendamustine containing chemotherapy in indolent lymphomas is possible. Results from the phase III study off B-R vs CHOP-R (NHL 1-2003 trial) of the StiL (Study Group Indolent Lymphomas, Germany). Blood 2009; 114:1048-9 (abstract 2679).